FOR RELEASE WEDNESDAY, MAY 3, 2017
BRIDGEWATER, NJ – Bausch + Lomb, a leading global eye health company, today announced that surgeons can sign up to “test drive” the new Stellaris Elite™ vision enhancement system, the company’s next generation phacoemulsification platform, at a wet lab in its booth (#2023) at the Academy Society of Cataract and Refractive Surgery (ASCRS) this week in Los Angeles, CA. The company announced the new platform received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in April.
“We know how critical hands-on experience can be when selecting new capital equipment, so we are thrilled to offer our customers the opportunity to test drive this new adaptable, dual-function surgical platform,” said Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb. “As the industry celebrates 50 years of phacoemulsification, we’re proud to help usher in the future with this innovative technology by demonstrating all of the features this next-generation machine has to offer.”
Among the many new cutting-edge innovations that Stellaris Elite features are Adaptive Fluidics™ and the Attune® energy management systems, which are designed to work synergistically to deliver responsiveness and optimized control throughout the entire procedure. Additionally, while traditional capital equipment has a decade-long life cycle, Stellaris Elite will offer surgeons the opportunity to add upgrades and enhancements continuously, allowing them to customize and expand their capabilities over time to provide optimal performance and long-term visual outcomes for their patients now and in the future. For example, this summer, the company plans to launch Stellaris Elite for retina applications, which will exclusively feature the Vitesse™ vitreous cutter, the first and only hypersonic, 100% open port vitrectomy system, which represents the first major vitreous removal innovation in 40 years.
During the interactive 30-minute wet lab sessions, surgeons will gain real time, hands-on experience with the new Stellaris Elite platform, as well as the VICTUS® femtosecond laser, and an extremely broad selection of intraocular lenses (IOLs) and delivery systems, which include the iSert® delivery system, a market-leading preloaded IOL, and the Crystalens® AO, TRULIGN® Toric, and the enVista® glistening-free acrylic IOLs. Attendees will have the opportunity to hear firsthand from the engineers and researchers who are responsible for the development of Bausch + Lomb’s surgical suite of technologies.
For more information and to schedule an appointment in the wet lab visit: www.testdrivebausch.com.
New Storz® Ophthalmic Instruments Offerings
The Bausch + Lomb Storz® ophthalmic instrument portfolio for cataract and refractive surgery will be on display and available for purchase at the company’s booth. The new Osher “No Fly” instrument set, developed in partnership with Bausch + Lomb and Robert Osher, M.D., professor of Ophthalmology at the College of Medicine of the University of Cincinnati and medical director emeritus of the Cincinnati Eye Institute, is the newest series of instruments added to the comprehensive Storz® line of products. The Osher “No Fly” set of cataract instruments were designed to work under overhead technology to help minimize the risk of instruments hitting attachments, such as aberrometers, that fall below the scope, potentially rendering them no longer sterile. The new instrument set will provide the same functionality as commonly used instruments in cataract procedures, but feature shorter handles to help improve surgeon’s maneuverability.
Bausch + Lomb’s Branded Ophthalmic Pharmaceuticals
Many of the company’s wide range of branded ophthalmic pharmaceuticals will be featured in the Bausch + Lomb booth. This includes PROLENSA® (bromfenac ophthalmic solution) 0.07%, which was introduced to the market five years ago and remains a widely recognized NSAID with approximately 2.2 million prescriptions since launch.1 Powered for penetration, PROLENSA® is an advanced bromfenac formulation to facilitate corneal penetration and target ocular tissues.2,3 Additionally, LOTEMAX® Gel (loteprednol etabonate ophthalmic gel) 0.5% is a corticosteroid used to treat post-operative inflammation and pain following ocular surgery. Bausch + Lomb’s loteprednol products have been trusted by eye care professionals since they were first introduced by providing efficacy to treat the FDA-approved indicated disease states with the established safety of loteprednol.
Featured Educational Programs
Bausch + Lomb will support a variety of educational events during the ASCRS meeting featuring a diverse group of highly regarded speakers. The full schedule of events includes:
Cataract-Focused Symposia on Sunday, May 7
Led by program chair, John Hovanesian, M.D., “Integrating Premium Technology for Excellent Outcomes,” will be open to meeting attendees on Sunday, May 7 at the Los Angeles Convention Center (West Hall B). The educational program will include the following faculty; Cynthia Matossian, M.D., Inder Paul Singh, M.D., and Mitch. C. Shultz, M.D. Registration and breakfast begins at 6 a.m., with the program commencing at 6:30 a.m. Attendees can register online at: http://meetings.eyeworld.org/bausch.
Industry Spotlight Theater
The Industry Spotlight Theater offered by ASCRS ASOA Symposium & Congress is a new series of exhibit hall-based educational programming designed to provide attendees the opportunity to learn about different ophthalmic products and categories. A distinguished group of speakers will moderate the sessions, several of which will include discussion of technologies from the Bausch + Lomb surgical portfolio. These events include:
Scientific Podium Presentations and Posters
20 podium presentations, e-posters, and films will feature Bausch + Lomb’s surgical technologies during the meeting. The full schedule includes:
Saturday, May 6
Ang, Robert. “Prospective Randomized Study Comparing Visual Outcomes of an Accommodating and Two Multifocal Intraocular Lens (IOLs): 5-Year Follow-up.” Saturday, May 6 at 3:36 p.m.; Room 402B.
Liang, Eva. “Effects of Co-Implantation with Capsular Tension Ring (CTR) in Patients Implanted with an Accommodating Intraocular Lens (IOL).” Saturday, May 6 at 3:27 p.m.; Room 402A.
McKee, Yuri. “Effectiveness of Femtosecond Laser Corneal Arcuate Incisions for Correction of Low-Grade Keratometric Astigmatism during Cataract Surgery.” Saturday, May 6 at 1:57 p.m.; Room 402A.
Page, Timothy. “Surgical Techniques and Intraoperative Events Associated with Vaulting of Accommodative Intraocular Lens (IOL).” Saturday, May 6 at 3:07 p.m.; Room 402B.
Whitman, Jeffrey. “Post-Operative Signs of Vault in Accommodative Intraocular Lens (IOL) and Post-Operative Management Techniques.” Saturday, May 6 at 3:02 p.m., Room 402B.
Stahl, Brian. “Potential Impact of Surgical Variables on Refractive Outcomes for Accommodative Intraocular Lens (IOL).” Saturday, May 6 at 3:17 p.m.; Room 402B.
Sunday, May 7
Harvey, Thomas. “Comparison of Visual Outcomes and Residual Refractive Cylinder of a Low-Toricity IOL and an Accommodative IOL.” Sunday, May 7 at 3:47 p.m.; Room 410.
Shultz, Mitchell. “Subjective and Objective Measurements of Enhanced Depth of Focus with Monofocal Intraocular Lens (IOL).” Sunday, May 7 at 8:47 a.m.; Room 409AB.
Whitman, Jeffrey. “Refractive and Visual Outcomes for Cataract Surgery following Radial Keratotomy.” Sunday, May 7 at 3:55 p.m.; Room 402A.
Monday, May 8
Liang, Eva. “Combined Treatment with Toric Accommodating Intraocular Lens (IOL) and Limbal Relaxing Incision (LRI) for Correction of Corneal Astigmatism.” Monday, May 8 at 2:05 p.m.; Room 402B.
O’Brien, Terrence P. “Scanning Electron Micrographic Comparison of Manual Capsulorhexis and Femtosecond Laser-Assisted Capsulotomy Methods.” Monday, May 8 at 2:07 p.m.; Room 402A.
Tyson, Farrell C. “Results of a Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of a New Acrylic Toric Intraocular Lens (IOL).” Monday, May 8 at 3:07 p.m.; Room 410.
Thompson, Vance. “Clinical Evaluation of the Effect of Capsulorhexis Diameter on Refractive Outcomes with Accommodative IOL.” Monday, May 8 at 3:47 p.m.; Room 410.
Solomon, Jonathan. “Reduction in Effect of Corneal Astigmatism with Low-Toricity Toric IOL in Cataract Patients.” Monday, May 8 at 3:52 p.m.; Room 410.
Tuesday, May 9
Page, Timothy. “Pre-Operative Risk Factors for Vault in Accommodative Intraocular Lens (IOL).” Tuesday, May 9 at 10:55 a.m.; Room 409A.
Berdahl, John. “Visual Refractive Outcomes with Limbal Relaxing Incisions in Accommodative Intraocular Lens Patients.” Poster available online May 5-9.
Cornell, Peter. “Accuracy to Refractive Target after Implantation with Accommodative IOL: Comparison of Three IOL Calculation Formulae.” Poster available online May 5-9.
Packer, Mark. “Optical Characteristics and Quality of Vision – Comparison of Diffractive Extended Depth of Focus and Aspheric Refractive IOLs.” Poster available online May 5-9.
Packer, Mark. “Comparison of Image Quality of Refractive and Diffractive IOLs with Shift in Pupil Center under Mesopic Conditions.” Poster available online May 5-9.
Shultz, Mitchell. “Comparative Analysis of Intraocular Pressure (IOP) Fluctuation between Two Adaptive Fluidics Phacoemulsification Systems.” Poster available online May 5-9.
Singh, Inder Paul. “OVD Release and Confirmation of a Free-Floating Anterior Capsule after Femtosecond-Assisted Cataract Surgery.” Film available online May 5-9.
Indications and Usage for PROLENSA®
PROLENSA® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Important Safety Information About PROLENSA®
Please see accompanying full Prescribing Information for PROLENSA®, here.
Indications and Usage for LOTEMAX® GEL
LOTEMAX® Gel (loteprednol etabonte ophthalmic gel) 0.5% is indicated for the treatment of post-operative inflammation and pain following ocular surgery.
Important Safety Information About LOTEMAX®
Please see accompanying full Prescribing Information for LOTEMAX® Gel, here.
About Bausch + Lomb
1. Data on file, Bausch & Lomb Incorporated.
2. PROLENSA Prescribing Information.
3. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398.
®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other product/brand names are trademarks of the respective owners.
© 2017 Bausch & Lomb Incorporated. MTB.0051.USA.17
News Media Contacts
Director, Corporate Communications, Bausch + Lomb
(908) 927-0683 or email@example.com
BioComm Network, on behalf of Bausch + Lomb
(973) 809-8590 or firstname.lastname@example.org
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.